-
Product Insights
NewNet Present Value Model: Oxurion NV’s THR-149
Empower your strategies with our Net Present Value Model: Oxurion NV's THR-149 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EEDVD-682 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EEDVD-682 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EEDVD-682 in Pancreatic Cancer Drug Details:EEDVD-682 is under development for treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – THR-149 in Diabetic Macular Edema
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.THR-149 in Diabetic Macular EdemaDrug Details:THR-149 is under development for treatment of diabetic macular edema associated...
-
Company Profile
Oxurion NV – Company Profile
Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements...
Add to Basket -
Product Insights
Medulloblastoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Medulloblastoma Pipeline Drugs Market Report Overview Medulloblastoma is the most common malignant brain tumor in children. Medulloblastoma by definition occurs in the cerebellum, which is the part of the brain located at the base of the skull, just above the brainstem. Symptoms associated with a Medulloblastoma include headaches in the morning that improve as the day goes on, recurrent vomiting, and difficulty walking and with balance. Medulloblastoma can spread to other areas of the central nervous system. Treatment includes options...
-
Product Insights
Retinal Vein Occlusion Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Retinal Vein Occlusion is a blockage in one of the veins returning blood flow from the retina. Its predisposing factors are atherosclerosis, macular edema, diabetes, high blood pressure, high cholesterol, and age. The Retinal Vein Occlusion pipeline market research report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action...
-
Product Insights
Net Present Value Model: THR-149
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model THR-149 Drug Details THR-149 is under...
-
Product Insights
Net Present Value Model: THR-687
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model THR-687 Drug Details THR-687 is under...